Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Chief Medical Officer | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 169,848 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 1,099 · Balance 169,848 F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:02 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 1,099 | $6.84 | $7,514.08 |
DisclosureSEC source: 0001193125-26-415528 · ownership.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,848 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 22:35 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001193125-26-389510 · ownership.xml · derivative · entry 2 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2036-09-08 F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 22:35 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389510 · ownership.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,947 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:03 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 1,100 | $11.16 | $12,271.16 |
DisclosureSEC source: 0001193125-26-383619 · ownership.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,947 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 23:06 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,306 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001193125-26-377207 · ownership.xml · derivative · entry 3 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,265 Underlying: Common Stock · 5,306 shares Expires 2035-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. F3 · derivative.exercise_date: 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 23:06 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 8,222 | $12.01 | $98,735.53 |
DisclosureSEC source: 0001193125-26-377207 · ownership.xml · nonDerivative · entry 2 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,047 F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. F2 · price: The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 23:06 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Exercise / conversionCommon Stock | 5,306 | $1.92 | $10,187.52 |
DisclosureSEC source: 0001193125-26-377207 · ownership.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 01:00 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 429 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001193125-26-357383 · ownership.xml · derivative · entry 3 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,571 Underlying: Common Stock · 429 shares Expires 2035-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. F2 · derivative.exercise_date: 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 01:00 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 429 | $12.00 | $5,148.00 |
DisclosureSEC source: 0001193125-26-357383 · ownership.xml · nonDerivative · entry 2 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,963 F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 01:00 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Exercise / conversionCommon Stock | 429 | $1.92 | $823.68 |
DisclosureSEC source: 0001193125-26-357383 · ownership.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. Read SEC document |
| May 19, 2026 Filed May 20, 2026 01:50 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 7,037 | $9.01 | $63,386.48 |
DisclosureSEC source: 0001193125-26-231507 · ownership.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,963 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The weighted average sale price for the transaction reported was $9.0076, and the range of prices were between $8.7404 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:48 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 102,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057668 · ownership.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| April 08, 2025 Filed Apr 25, 2025 21:07 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001415889-25-011379 · form4-04252025_090459.xml · derivative · entry 2 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-04-07 F2 · derivative.exercise_date: 25% of the shares initially subject to the option will vest and become exercisable on April 8, 2026, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months. Read SEC document |
| April 08, 2025 Filed Apr 25, 2025 21:07 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011379 · form4-04252025_090459.xml · nonDerivative · entry 1 Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.